Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;12(4):e2427.
doi: 10.1002/mgg3.2427.

Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review

Affiliations
Review

Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review

Kanako Higashi et al. Mol Genet Genomic Med. 2024 Apr.

Abstract

Gaucher disease (GD) is a lysosomal storage disorder caused by a deficiency in the GBA1-encoded enzyme, β-glucocerebrosidase. Enzyme replacement therapy is ineffective for neuronopathic Gaucher disease (nGD). High-dose ambroxol has been administered as an alternative treatment for a group of patients with nGD. However, little is known about the clinical indication and the long-term outcome of patients after ambroxol therapy. We herein report a case of a female patient who presented with a progressive disease of GD type 2 from 11 months of age and had the pathogenic variants of p.L483P (formerly defined as p.L444P) and p.R502H (p.R463H) in GBA1. A combined treatment of imiglucerase with ambroxol started improving the patient's motor activity in 1 week, while it kept the long-lasting effect of preventing the deteriorating phenotype for 30 months. A literature review identified 40 patients with nGD, who had received high-dose ambroxol therapy. More than 65% of these patients favorably responded to the molecular chaperone therapy, irrespective of p.L483P homozygous, heterozygous or the other genotypes. These results highlight the long-lasting effect of ambroxol-based chaperone therapy for patients with an expanding spectrum of mutations in GBA1.

Keywords: Gaucher disease; ambroxol; chaperone; genotype; glucocerebrosidase; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest concerning this work.

Figures

FIGURE 1
FIGURE 1
Clinical profiles and the treatment course of the present case. (a) May‐Grunwald‐Giemsa staining for Gaucher cells (arrows) in the bone‐marrow smear. Scale, 10 μm. (b) Sagittal T1‐weighted (left) and axial fluid‐attenuated inversion recovery (FLAIR, middle) image on day 24 of admission. No parenchymal lesion was detected in the FLAIR image at 3 months after discharge (right). (c) Clinical course of the patient. Treatments are shown at the top. Neurological findings and laboratory data are depicted in the middle and lower schemes, respectively. ACE, angiotensin‐converting enzyme; TRACP‐5b, Tartrate‐Resistant Acid Phosphatase 5b.
FIGURE 2
FIGURE 2
A mutational landscape of 40 patients who received ambroxol therapy for neuronopathic Gaucher disease. (a) The gene structure of GBA1 located at chromosome 1q22. Shaded boxes represent the 11 protein‐coding exons spanning the 6.8‐kb region in the negative strand of the human genome. The left‐to‐right direction corresponds to that of transcription. Annotations indicate 23 pathogenic variants identified in patients with neuronopathic Gaucher disease. Horizontal bars represent the domain structure of GCase. Red: mutant alleles identified in the present patient. All the 40 patients having these variants were reported to receive the ambroxol treatment. (b) Pie chart indicates the number and frequency (%) of mutant alleles among 80 alleles identified in the 40 patients (panel a). —, unidentified variant. (c) A stereographic structure of GCase (UniProt: A0A068F658). The location of amino acid residues harboring nGD‐associated variants is schematically shown.

References

    1. Bendikov‐Bar, I. , Maor, G. , Filocamo, M. , & Horowitz, M. (2013). Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells, Molecules & Diseases, 50(2), 141–145. 10.1016/j.bcmd.2012.10.007 - DOI - PMC - PubMed
    1. Charkhand, B. , Scantlebury, M. H. , Narita, A. , Zimran, A. , & Al‐Hertani, W. (2019). Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso‐Gb1) levels in two Canadian patients with type 3 Gaucher disease. Molecular Genetics and Metabolism Reports, 20, 100476. 10.1016/j.ymgmr.2019.100476 - DOI - PMC - PubMed
    1. Charrow, J. , & Scott, C. R. (2015). Long‐term treatment outcomes in Gaucher disease. American Journal of Hematology, 90(Suppl 1), S19–S24. 10.1002/ajh.24056 - DOI - PubMed
    1. Chu, S. Y. , Chien, C. C. , Hwu, W. L. , Wang, P. J. , & Chien, Y. H. (2020). Early initiation of high‐dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant. Blood Cells, Molecules & Diseases, 81, 102402. 10.1016/j.bcmd.2019.102402 - DOI - PubMed
    1. Ciana, G. , Dardis, A. , Pavan, E. , Da Riol, R. M. , Biasizzo, J. , Ferino, D. , & Bembi, B. (2020). In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy. Molecular Genetics and Metabolism Reports, 25, 100678. 10.1016/j.ymgmr.2020.100678 - DOI - PMC - PubMed